Home Products Antibodies Primary Antibodies 14 007 937
14-007-937

CD7 Monoclonal Antibody (eBio124-1D1 (124-1D1)), eBioscience™, Invitrogen™

Manufacturer: Invitrogen

Select a Size

Pack Size SKU Availability Price
Each 14-007-937-Each In Stock ₹ 1,03,831.85

14-007-937 - Each

₹ 1,03,831.85

In Stock

Quantity

1

Base Price: ₹ 1,03,831.85

GST (18%): ₹ 18,689.733

Total Price: ₹ 1,22,521.583

Antigen

CD7

Classification

Monoclonal

Concentration

0.5 mg/mL

Formulation

PBS with 0.09% sodium azide; pH 7.2

Gene Accession No.

P09564

Gene Symbols

CD7

Purification Method

Affinity chromatography

Regulatory Status

RUO

Gene ID (Entrez)

924

Content And Storage

4° C

Form

Liquid

Applications

Flow Cytometry

Clone

eBio124-1D1 (124-1D1)

Conjugate

Unconjugated

Gene

CD7

Gene Alias

Cd7; CD7 antigen; CD7 antigen (p41); Cd7 molecule; GP40; LEU-9; p41 protein; T-cell antigen CD7; T-cell leukemia antigen; T-cell surface antigen Leu-9; Tp40; TP41

Host Species

Mouse

Quantity

2 mg

Primary or Secondary

Primary

Target Species

Human

Product Type

Antibody

Isotype

IgG1 κ

Description

  • CD7 (gp40, Leu9) is a 40 kDa member of the immunoglobulin gene superfamily
  • CD7 contains N-terminal amino acids 1-107 are highly homologous to Ig kappa-L chains whereas the carboxy-terminal region of the extracellular domain is proline-rich and has been postulated to form a stalk from which the Ig domain projects
  • CD7 is expressed on the majority of immature and mature T-lymphocytes, and T cell leukemia
  • Further, CD7 is also found on natural killer cells, a small subpopulation of normal B cells and on malignant B cells
  • Cross-linking surface CD7 positively modulates T cell and NK cell activity as measured by calcium fluxes, expression of adhesion molecules, cytokine secretion and proliferation
  • CD7 associates directly with phosphoinositol 3'-kinase
  • CD7 ligation induces production of D-3 phosphoinositides and tyrosine phosphorylation
  • Expression of CD7 is an important marker used in leukemia diagnostics.